ClinVar Miner

Submissions for variant NM_000051.4(ATM):c.6198+1del

dbSNP: rs2136132894
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001911628 SCV002168187 pathogenic Ataxia-telangiectasia syndrome 2021-01-29 criteria provided, single submitter clinical testing This sequence change affects donor splice site in intron 42 of the ATM gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is not present in population databases (ExAC no frequency). Variants affecting this donor splice site have been observed as homozygous or in combination with another ATM variant in several individuals affected with ataxia telangiectasia (PMID: 9463314, 21459046, 26915675, 26220245). In addition, they have been reported as heterozygous in individuals affected with ATM-related cancers (PMID: 29909963, 16832357, 21792198). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.